Table 2.
Subgroup analyses of patients aged at least 70 years in nonspecific clinical trials.
| Author [year] | Total no. of patients/no. patients ≥70 years | Treatment arms | Response rate <70 years/ ≥70 years (%) | Median survival time <70 years/ ≥70 years | 1-year survival rate <70 years/ ≥70 years (%) |
|---|---|---|---|---|---|
| Langer [2002] | 574/86 | CDDP + VP16 versus CDDP + Pacli | 21.5/23.3* | 9.1*/8.5 months | 38*/29 |
| Lilenbaum [2005] | 561/155 | Carbo + Pacli versus Pacli | 28*/36 | 9*/8 months | 38*/33 |
| 15/21 | 6.8/5.8 months | 35/31 | |||
| Belani [2005] | 1218/401$ | CDDP + Doc versus Carbo + Doc versus CDDP + VNR | 11.0/12.6 months | 44/52 | |
| 9.7/9 months | 37/39 | ||||
| 10.1/9.9 months | 41/41 | ||||
| Ansari [2011] | 1135/338 | Carbo + Gem versus Pacli + Gem versus Carbo + Pacli | 30.1/28.2 | 7.7/8.8/8.0/ 7.2 months | |
| 24.8/24.4 | 8.9/9.8/5.9/ 7.8 months | ||||
| ‡ | 9.4/8.4/6.1/ 7.9 months§ | ||||
| Blanchard [2011] | 616/122 | CDDP + VNR versus Carbo + Pacli | 27/30 | 9/7 months (p = 0.04) | 40/27 |
*
Global percentage or median survival time for the two arms together.
$
401 patients aged ≥65 years.
‡
Response rate by categories of age, the three arms being combined: <70 years, 70–74 years, 75–79 years, 80 years and more.
§
Median survival by arm and age categories. No significant difference.
Carbo, carboplatin; CDDP, cisplatin; Doc, docetaxel; Gem, gemcitabine; Pacli, paclitaxel; VNR, vinorelbine; VP16, etoposide.